Why scientists are racing to develop more COVID antivirals.

Subjects

Subjects :

Adenosine Monophosphate administration & dosage
Adenosine Monophosphate analogs & derivatives
Adenosine Monophosphate pharmacology
Adenosine Monophosphate therapeutic use
Administration, Oral
Alanine administration & dosage
Alanine analogs & derivatives
Alanine pharmacology
Alanine therapeutic use
Antiviral Agents administration & dosage
Antiviral Agents pharmacology
Antiviral Agents supply & distribution
COVID-19 mortality
COVID-19 prevention & control
COVID-19 Vaccines supply & distribution
Cytidine administration & dosage
Cytidine analogs & derivatives
Cytidine pharmacology
Cytidine therapeutic use
Drug Approval
Drug Combinations
Drug Therapy, Combination
Hospitalization statistics & numerical data
Humans
Hydroxylamines administration & dosage
Hydroxylamines pharmacology
Hydroxylamines therapeutic use
Lactams administration & dosage
Lactams pharmacology
Lactams therapeutic use
Leucine administration & dosage
Leucine pharmacology
Leucine therapeutic use
Medication Adherence
Molecular Targeted Therapy
Mutagenesis
Nitriles administration & dosage
Nitriles pharmacology
Nitriles therapeutic use
Proline administration & dosage
Proline pharmacology
Proline therapeutic use
Public-Private Sector Partnerships economics
Ritonavir administration & dosage
Ritonavir pharmacology
Ritonavir therapeutic use
SARS-CoV-2 enzymology
SARS-CoV-2 genetics
Antiviral Agents therapeutic use
COVID-19 virology
Drug Development trends
Drug Resistance, Viral drug effects
Drug Resistance, Viral genetics
Research Personnel
SARS-CoV-2 drug effects
COVID-19 Drug Treatment

Details

Language :

English

ISSN :

1476-4687

Volume :

601

Issue :

7894

Database :

MEDLINE

Journal :

Nature

Publication Type :

Periodical

Accession number :

35064230

Full Text :

https://doi.org/10.1038/d41586-022-00112-8